363 related articles for article (PubMed ID: 24107395)
1. Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population.
Gordon SC; Lamerato LE; Rupp LB; Li J; Holmberg SD; Moorman AC; Spradling PR; Teshale EH; Vijayadeva V; Boscarino JA; Henkle EM; Oja-Tebbe N; Lu M;
Clin Gastroenterol Hepatol; 2014 May; 12(5):885-93. PubMed ID: 24107395
[TBL] [Abstract][Full Text] [Related]
2. Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir-A Propensity Score-Matched Study.
Nguyen MH; Yang HI; Le A; Henry L; Nguyen N; Lee MH; Zhang J; Wong C; Wong C; Trinh H
J Infect Dis; 2019 Jan; 219(1):10-18. PubMed ID: 29982737
[TBL] [Abstract][Full Text] [Related]
3. High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load.
Tseng TC; Liu CJ; Hsu CY; Hong CM; Su TH; Yang WT; Chen CL; Yang HC; Huang YT; Fang-Tzu Kuo S; Liu CH; Chen PJ; Chen DS; Kao JH
Gastroenterology; 2019 Dec; 157(6):1518-1529.e3. PubMed ID: 31470004
[TBL] [Abstract][Full Text] [Related]
4. Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals.
Lee HW; Kim SU; Park JY; Baatarkhuu O; Kim DY; Ahn SH; Han KH; Kim BK
Clin Transl Gastroenterol; 2019 Jun; 10(6):e00036. PubMed ID: 31107725
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
[TBL] [Abstract][Full Text] [Related]
6. Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B.
Choi WM; Kim GA; Choi J; Choi GH; Lee YB; Sinn DH; Lim YS
Gut; 2024 Mar; 73(4):649-658. PubMed ID: 37813567
[TBL] [Abstract][Full Text] [Related]
7. Reduction of chronic hepatitis B-related hepatocellular carcinoma with anti-viral therapy, including low risk patients.
Lin D; Yang HI; Nguyen N; Hoang J; Kim Y; Vu V; Le A; Chaung K; Nguyen V; Trinh H; Li J; Zhang J; Hsing A; Chen CJ; Nguyen MH
Aliment Pharmacol Ther; 2016 Oct; 44(8):846-55. PubMed ID: 27549411
[TBL] [Abstract][Full Text] [Related]
8. Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection.
Kurokawa M; Hiramatsu N; Oze T; Yakushijin T; Miyazaki M; Hosui A; Miyagi T; Yoshida Y; Ishida H; Tatsumi T; Kiso S; Kanto T; Kasahara A; Iio S; Doi Y; Yamada A; Oshita M; Kaneko A; Mochizuki K; Hagiwara H; Mita E; Ito T; Inui Y; Katayama K; Yoshihara H; Imai Y; Hayashi E; Hayashi N; Takehara T
J Gastroenterol; 2012 May; 47(5):577-85. PubMed ID: 22231575
[TBL] [Abstract][Full Text] [Related]
9. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase.
Huang DQ; Tran A; Yeh ML; Yasuda S; Tsai PC; Huang CF; Dai CY; Ogawa E; Ishigami M; Ito T; Kozuka R; Enomoto M; Suzuki T; Yoshimaru Y; Preda CM; Marin RI; Sandra I; Tran S; Quek SXZ; Khine HHTW; Itokawa N; Atsukawa M; Uojima H; Watanabe T; Takahashi H; Inoue K; Maeda M; Hoang JK; Trinh L; Barnett S; Cheung R; Lim SG; Trinh HN; Chuang WL; Tanaka Y; Toyoda H; Yu ML; Nguyen MH
Hepatology; 2023 Nov; 78(5):1558-1568. PubMed ID: 37184202
[TBL] [Abstract][Full Text] [Related]
10. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection.
Hosaka T; Suzuki F; Kobayashi M; Seko Y; Kawamura Y; Sezaki H; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
Hepatology; 2013 Jul; 58(1):98-107. PubMed ID: 23213040
[TBL] [Abstract][Full Text] [Related]
11. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B.
Kim WR; Loomba R; Berg T; Aguilar Schall RE; Yee LJ; Dinh PV; Flaherty JF; Martins EB; Therneau TM; Jacobson I; Fung S; Gurel S; Buti M; Marcellin P
Cancer; 2015 Oct; 121(20):3631-8. PubMed ID: 26177866
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B Virus Combo Mutations Improve the Prediction and Active Prophylaxis of Hepatocellular Carcinoma: A Clinic-Based Cohort Study.
Yin J; Wang J; Pu R; Xin H; Li Z; Han X; Ding Y; Du Y; Liu W; Deng Y; Ji X; Wu M; Yu M; Zhang H; Wang H; Thompson TC; Ni W; Cao G
Cancer Prev Res (Phila); 2015 Oct; 8(10):978-88. PubMed ID: 26290395
[TBL] [Abstract][Full Text] [Related]
13. Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis.
Hoang JK; Yang HI; Le A; Nguyen NH; Lin D; Vu VD; Chaung K; Nguyen V; Trinh HN; Li J; Zhang JQ; Chen CJ; Nguyen MH
Medicine (Baltimore); 2016 Aug; 95(31):e4433. PubMed ID: 27495067
[TBL] [Abstract][Full Text] [Related]
14. Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up.
Zhang W; Wang X; Wang Y; Zhao X; Duan W; Wang Q; Wu X; Kong Y; Ma H; You H; Ou X; Jia J
Medicine (Baltimore); 2017 Nov; 96(44):e8454. PubMed ID: 29095292
[TBL] [Abstract][Full Text] [Related]
15. Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China.
Yip TC; Wong VW; Chan HL; Tse YK; Lui GC; Wong GL
Gastroenterology; 2020 Jan; 158(1):215-225.e6. PubMed ID: 31574268
[TBL] [Abstract][Full Text] [Related]
16. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.
Kim SS; Hwang JC; Lim SG; Ahn SJ; Cheong JY; Cho SW
Am J Gastroenterol; 2014 Aug; 109(8):1223-33. PubMed ID: 24890440
[TBL] [Abstract][Full Text] [Related]
17. Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated With Entecavir: Results of the ENUMERATE Study.
Ahn J; Lim JK; Lee HM; Lok AS; Nguyen M; Pan CQ; Mannalithara A; Te H; Reddy KR; Trinh H; Chu D; Tran T; Lau D; Leduc TS; Min A; Trong Le L; Bae H; Van Tran S; Do S; Hann HW; Wong C; Han S; Pillai A; Park JS; Tong M; Scaglione S; Woog J; Kim WR
Am J Gastroenterol; 2016 Sep; 111(9):1297-304. PubMed ID: 27325221
[TBL] [Abstract][Full Text] [Related]
18. Association of adjuvant antiviral therapy with risk of cancer progression and deaths in patients with hepatitis-B-virus-related hepatocellular carcinoma following curative treatment: a nationwide cohort study.
Yeh YC; Liu CJ; Kuo RN; Lai CL; Shau WY; Chen PJ; Lai MS
PLoS One; 2014; 9(7):e102051. PubMed ID: 25025231
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.
Fung J; Cheung KS; Wong DK; Mak LY; To WP; Seto WK; Lai CL; Yuen MF
Hepatology; 2018 Aug; 68(2):462-472. PubMed ID: 29534307
[TBL] [Abstract][Full Text] [Related]
20. Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy.
Alshuwaykh O; Daugherty T; Cheung A; Goel A; Dhanasekaran R; Ghaziani TT; Ahmed A; Dronamraju D; Kumari R; Kwong A; Nguyen M; Kim WR; Kwo PY
Hepatol Commun; 2022 Nov; 6(11):3052-3061. PubMed ID: 36004713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]